Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

NervGen: Are amazing human trial results leaking out?

“We are very excited! We are very, very excited!” So says Dr. Monica Perez, who is running the first human trial for a potential new wonder drug being developed by a tiny but well-financed life sciences start-up, NervGen Pharma Corp. ...
Knox Henderson | July 2, 2024 |

Analyst: Acquisition by Colorado-Based Specialty Pharma 'Could Bolster Revenue 400%'

The benefits and terms of the agreement are outlined in a Ladenburg Thalmann report. In a Sept. 18 research note, Ladenburg Thalmann analyst Jeffrey Cohen reported that Aytu BioScience Inc. (AYTU:NASDAQ) signed a definitive agreement to acquire Innovus Pharmaceutic...
Streetwise Reports | September 25, 2019 |

Biopharma 'Keeps Executing and Securing Milestones'

The company's latest achievement and partnership potential are addressed in a ROTH Capital Partners report. In a Dec. 12 research note, ROTH Capital Partners analyst Yasmeen Rahimi reported that Daré Bioscience Inc. (DARE:NASDAQ) received U.S. Food and Drug Adminis...
Streetwise Reports | December 19, 2019 |

Trump Impeached in the House! Is It Time for Gold Now?

Last week, the House voted to impeach Donald Trump. This is the third time in the U.S. history such an event has happened to the sitting President. What does it imply for the gold market? Trump’s Impeachment, Explained On Wednesday, the House of Represe...
Arkadiusz Sieron | December 27, 2019 |

Biotech Announces Deal with Bayer on Non-Hormonal Contraception

Details of the arrangement and an update on the company's pipeline are provided in a Dawson James report. In a Jan. 13 research note, Dawson James Securities analyst Jason Kolbert reported that Daré Bioscience Inc. (DARE:NASDAQ) partnered with Bayer, the company beh...
Streetwise Reports | January 16, 2020 |

A massive bull market is building for gold

Imagine, if you will, there was no coronavirus. No haz-mat suits, medical masks & gloves, no make-shift morgues. No terminally ill patients hooked up to ventilators, no horrible deaths without love ones close, no lockdowns, no social distancing, no deserted streets, no bailo...
Richard (Rick) Mills | April 17, 2020 |

China dominates worlds supply chains

Cleaner skies owing to covid-19 lockdowns appear to be the silver lining of the global economy crashing to a sudden halt in March. In fact new evidence shows that high-polluting energy sources were on the wane, even before the coronavirus pandemic. According to the I...
Richard (Rick) Mills | May 11, 2020 |